← All trials
NCT06646354
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2025
- Primary completion
- Apr 15, 2025
- Completion date
- Dec 31, 2028
- First posted
- Oct 17, 2024
- Last posted
- Oct 17, 2024
- Enrollment
- 125
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- HyundaiLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.